At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 263 enrolled
Drug / intervention
Dexycudrug
Likely dose
Dexycu 517 μg (5 μL of 103.4 μg/μL dexamethasone solution) as single intraocular injectionAI-extracted
Key inclusion· 1
- ✓Male or female subjects over 40 years of age scheduled for cataract phacoemulsification surgery with intraocular lens implantation
Key exclusion· 5
- ✕Known hypersensitivity to dexamethasone or any component of Dexycu
- ✕History of intraocular inflammation of any cause in either eye
- ✕Presence of corneal abnormalities or malnutrition
- ✕Baseline intraocular pressure (IOP) >21 mmHg in the test eye at screening, regardless of anti-glaucoma monotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real-world Study to Evaluate the Efficacy and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associated With Cataract Surgery
In Brief
A Phase 4 clinical trial evaluating Dexycu for Inflammation and Cataract. Completed, enrolled 263 participants across 2 sites.
Detailed Summary
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Cataract
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
Enrollment StartOct 2021
Primary CompletionJul 2023
Study CompletionDec 2023
First PostedJul 2024
TodayJul 2026
First PostedJul 12, 2024
Enrollment StartOct 28, 2021
Primary CompletionJul 8, 2023
Study CompletionDec 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.0 years ago
Interventions
Dexycudrug
single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone